Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. leukeyolk

LEUKEYOLK SIGNED

Uncovering the origin and mechanisms of Down syndrome-associated leukaemia through human induced pluripotent stem cell-derived haemopoiesis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LEUKEYOLK project word cloud

Explore the words cloud of the LEUKEYOLK project. It provides you a very rough idea of what is the project "LEUKEYOLK" about.

leukaemogenesis    contribution    leukemias    interrogate    independent    malignancies    derives    nurture    shown    rarely    lastly    stem    fp7    cell    origin    landscape    pluripotent    yolk    source    recapitulation    developmental    area    embryogenesis    ipsc    hscs    molecular    elucidated    therapies    transcriptional    malignancy    extensive    cancer    shift    vitro    haemopoiesis    myeloproliferative    disorder    waves    primitive    onset    assays    leukaemias    disease    gata1    generating    followed    hypothesis    syndrome    sac    devoid    appreciated    ipscs    competitiveness    childhood    ds    transient    patient    embryonic    cells    megakaryoblast    first    megakaryocytic    hypothesise    functional    supports    differentiation    mechanisms    ys    isoform    hyperproliferation    erythromyeloid    least    paradigm    definitive    lineages    designing    utero    paradigmatic    tmd    perinatal    hsc    suggests    haemopoietic    compelling    myeloid    differentiating    dissecting    beginning    progenitors    mutations    emp    life    broad    ec    patients    vivo   

Project "LEUKEYOLK" data sheet

The following table provides information about the project.

Coordinator		 OSPEDALE SAN RAFFAELE SRL 

Organization address
address: VIA OLGETTINA 60
city: MILANO
postcode: 20132
website: www.hsr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Total cost 168˙277 €
 EC max contribution 168˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OSPEDALE SAN RAFFAELE SRL IT (MILANO) coordinator 168˙277.00

Map

 Project objective

This project aims at dissecting the contribution of yolk sac (YS)-derived haemopoietic progenitors to childhood leukaemias, whose early onset suggests an embryonic origin. Using induced pluripotent stem cell (iPSC) differentiation, we will determine the origin of the Down syndrome-associated transient myeloproliferative disease (DS-TMD), paradigmatic example of perinatal malignancy. TMD, due to megakaryoblast hyperproliferation, has an in utero origin. This supports the compelling hypothesis of a haemopoietic stem cell (HSC)-independent origin of DS-TMD, as during embryogenesis there are at least 3 waves of progenitors with megakaryocytic potential. A first primitive program, followed by the erythromyeloid progenitors (EMP), both YS-derived and devoid of HSC potential; lastly a definitive program, generating HSCs and all haemopoietic lineages. By differentiating iPSCs from a DS-TMD patient through recapitulation of embryonic development, we will interrogate the contribution of primitive, EMP and definitive haemopoiesis to DS-TMD with in vitro/in vivo functional assays. Moreover, we will investigate the molecular mechanisms triggering the disease. As mutations leading to a short GATA1 isoform occur in all cases of DS-TMD, we will analyse how this affects the transcriptional landscape of the cells relevant to the disease. We hypothesise that DS-TMD derives from a rarely appreciated developmental program (the EMP), whose life-long contribution is only beginning to be elucidated. Determining the developmental source and mechanisms of this disorder could help designing new therapies for myeloid malignancies in non-DS patients and could lead to a paradigm shift in the field of haemopoiesis and leukaemogenesis. Research on cancer and childhood leukemias is of broad interest for the EC, as shown by the extensive funding of projects on this topic within the FP7. Our project will further nurture this research area, contributing to increasing European research competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKEYOLK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEUKEYOLK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MNSWLGM (2019)

An optofluidic platform based on liquid-gradient refractive index microlens for the isolation and quantification of extracellular vesicles

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More